In The Claims:

Please add the following new claims:

--21. A method for purifying a polypeptide having an amino acid sequence shown in SEQ ID NO:1 from a biological sample, comprising:

(a) providing an affinity matrix comprising an antibody that selectively binds to said polypeptide bound to a solid support;

(b) contacting the biological sample with the affinity matrix-polypeptide complex;

(c) separating the affinity matrix-polypeptide complex from the remainder of the biological sample; and

(d) releasing the polypeptide from the affinity matrix.

22. A method for identifying a compound that binds to a polypeptide having an amino acid sequence of SEQ ID NO:1, said method comprising the steps of:

(a) contacting a polypeptide, or a cell expressing said with a test compound; and

(b) determining whether the polypeptide binds to the test compound.

23. The method of claim 22, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

(a) detection of binding by direct detecting of test compound/polypeptide binding;

(b) detection of binding using a competition binding assay; and

(c) detection of binding using an assay for GPCR-like-mediated signal transduction.

24. A method for screening a cell to identify an agent that binds with a polypeptide having an amino acid sequence shown in SEQ ID NO:1 in said cell, said method comprising contacting said cell with an agent and detecting an interaction between said polypeptide and said agent.

25. A method for screening a cell to identify an agent that modulates the expression level or activity of the polypeptide having an amino acid sequence in SEQ ID NO:1 in a cell, said method comprising contacting said cell with an agent and measuring the level or activity of said polypeptide.

26. The method of claim 25, wherein said cell is an immune cell.

B1 Cont.

27. The method of claim 25, wherein said agent increases the level or activity of said polypeptide.

28. The method of claim 25, wherein said agent decreases the level or activity of said polypeptide.

29. A method for modulating the activity of a polypeptide having an amino acid sequence shown in SEQ ID NO:1 in a cell comprising contacting said cell with a compound that binds to said polypeptide in a sufficient concentration to modulate the

activity of the polypeptide.

30. The method of claim 29, wherein the activity is modulated in a subject with an immune disorder.

31. A method for modulating an immune response in a mammal, said method comprising administering to said mammal a therapeutically effective amount of a polypeptide or its corresponding antibody, wherein said polypeptide is selected from the group consisting of:

(a) an isolated polypeptide having an amino acid sequence shown in SEQ ID NO:1;

(b) an isolated polypeptide having the amino acid sequence of SEQ ID NO:1 with conservative amino acid substitutions; and

(c) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:1

B1 Cont.

32. A method for modulating a Th2 response in a mammal said comprising administering to said mammal a therapeutically effective amount of a polypeptide or its corresponding antibody, wherein said polypeptide is selected from the group consisting of:

(a) an isolated polypeptide having an amino acid sequence shown in SEQ ID NO:1;

(b) an isolated polypeptide having the amino acid sequence of SEQ ID NO:1 with conservative amino acid substitutions; and

(c) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:1

33. A method for modulating G-protein coupled receptor expression in disease states of a patient, comprising contacting a tissue from said patient with an isolated antibody that selectively binds to the polypeptide having an amino acid sequence shown in SEQ ID NO:1 in a sufficient concentration to modulate G-protein coupled receptor expression.

34. The method of claim 33, wherein the G-protein coupled receptor expression is involved in signal transduction.

35. The method of claim 33, wherein the G-protein coupled receptor expression is involved in immunity.

B1 Cont

36. The method of claim 35, wherein the G-protein coupled receptor expression is involved in cytokine production.

37. The method of claim 36, wherein the G-protein coupled receptor expression is involved in IL-4 and IL-5 expression.--